No­var­tis mar­ket­ing vets move on to new com­mer­cial roles in biotech

The com­mer­cial staffers with No­var­tis or oth­er Big Phar­mas on their ré­sumés are still find­ing open arms wait­ing for them on the biotech side of the busi­ness as small­er and small­er drug de­vel­op­ers step up mar­ket­ing ef­forts in a hunt for their first ap­provals.

While Im­muno­core was cel­e­brat­ing its first big win at the FDA with an ap­proval for its first mar­ket­ed drug to­day, a close biotech cousin was lay­ing the foun­da­tion for its own hoped-for piv­ot to com­mer­cial­iza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER